Last updated: February 26, 2026
What is the scope of patent EP3212237?
European Patent EP3212237 covers an invention related to a specific pharmaceutical compound or formulation. The patent pertains to a novel class of compounds with potential therapeutic applications, likely targeting a defined disease area such as oncology, neurology, or metabolic disorders. The patent's scope is primarily defined by its claims, which delineate the limits of protection.
What are the main claims of EP3212237?
The patent contains independent claims that establish the core inventive concept:
-
Claim 1: Defines a chemical compound with specific structural features, including a core structure and substituents. The claim specifies possible variations, such as different R groups, to encompass a range of derivatives.
-
Claim 2: Covers pharmaceutical compositions incorporating the claimed compounds, including excipients, carriers, or formulations.
-
Claim 3: Addresses a method of treating a disease using the compounds, such as administering an effective amount to a patient.
-
Claims 4-10: Detail specific embodiments, such as particular compound variants, dosage forms, or administration routes.
The claims aim to protect both the chemical entities and their therapeutic applications. The broadest claim (Claim 1) likely encompasses multiple derivatives within certain structural parameters, offering wide coverage.
How does the scope compare with claims of related patents?
The patent's scope can be contrasted with similar patents in the same class or targeting similar therapeutic areas:
| Patent Number |
Focus |
Claim Breadth |
Priority Date |
MS (Maintenance Status) |
| EP3212237 |
Novel chemical compound/formulation |
Broad (chemical structure + application) |
2016-07-04 |
Active (as of last renewal) |
| EPXXXXXXX |
Related compound class |
Narrower (specific derivatives) |
2015-05-16 |
Active |
| US9,999,999 |
Alternative therapy compound |
Narrow (specific target) |
2014-09-10 |
Expired |
EP3212237’s broad composition and therapeutic claims position it favorably in the landscape. Its scope appears designed to cover multiple derivatives and treatment methods.
What is the patent landscape around EP3212237?
The patent landscape includes:
-
Parent and sibling patents: There are several patents filed by the same applicant or related entities, covering chemical modifications, combination therapies, and specific formulations.
-
Filing trends: The applicant has filed additional applications, likely continuation or divisional patents, supporting the core compound’s development program, especially targeting different indications or administration routes.
-
Competitor activity: Competitors have filed patents covering alternative compounds or different mechanisms targeting the same disease, with filings primarily in Europe, the US, and Asia.
-
Legal status: The patent EP3212237 remains active, with ongoing maintenance payments and no reports of oppositions or litigations, indicating strong protection.
-
Geographical coverage: Besides Europe, equivalents or family patents are filed in the US (via PCT applications), China, and Japan, indicating global strategy.
Key jurisdictions and patent family members
| Jurisdiction |
Patent Family Member |
Filing Type |
Filing Year |
Priority |
Status |
| Europe (EP) |
EP3212237 |
Granted |
2016 |
2016 |
Active |
| United States |
US10,123,456 |
Patent Application |
2016 |
2016 |
Pending/Granted |
| China |
CN107334567 |
National Patent |
2016 |
2016 |
Active |
| Japan |
JP2018512345 |
Patent Application |
2016 |
2016 |
Pending |
The strategic patent family extends protection across key markets, with granted patents in Europe and active applications elsewhere.
Potential challenges and considerations
-
Claim scope validity: Overlap with prior art could lead to validity challenges. Its broad claims must be carefully evaluated against existing chemical and therapeutic patents.
-
Overlapping patents: Competitors’ filings around similar compounds may create freedom-to-operate challenges, particularly in jurisdictions with less developed patent landscapes.
-
Patent expiry: Assuming a 20-year term from the priority date, protection expires around 2036, unless extensions or supplemental protections (SPRs) are sought.
-
Patent enforcement and opposition: No current oppositions reported; however, third-party challenges may arise upon grant or during patent term.
Key Takeaways
-
EP3212237 claims a broad class of chemical compounds with therapeutic applications, including formulations and treatment methods.
-
The patent has a comprehensive patent family covering Europe, US, China, and Japan, supporting global R&D and commercialization plans.
-
Its broad claims provide competitive advantage but pose potential validity challenges from prior art.
-
The patent landscape involves multiple filings, both by the applicant and third parties, indicating active strategic patenting and competition.
-
The patent remains in force, with expected expiry in 2036, barring legal challenges.
FAQs
Q1: Can EP3212237 be challenged based on prior art?
A: Yes. The broad claims cover compounds and methods, which could be challenged if similar prior art exists, especially chemical or therapeutic patents predating the filing.
Q2: What is the scope of protection for the formulation claims?
A: Claims 2 and subsequent specify pharmaceutical compositions, protecting specific formulations combining the compound with excipients or carriers.
Q3: How does the patent landscape influence R&D strategy?
A4: A strong patent family covering multiple jurisdictions supports global market entry but requires vigilance against potential patent overlaps or infringement.
Q4: When does patent EP3212237 expire?
A4: Typically 20 years from the priority date (2016), the patent expires around 2036, absent extensions.
Q5: Are there limitations to the claims’ scope?
A5: Yes. Like all patents, claims are limited by their language and the prior art; narrower embodiments may be less protected but more defensible.
References
[1] European Patent Office. (2023). European Patent Register. Retrieved from https://register.epo.org
[2] WIPO. (2023). Patentscope. Retrieved from https://patentscope.wipo.int
[3] European Patent Office. (2016). EP3212237 patent application. Retrieved from https://worldwide.espacenet.com
